FDA Appeal In Zocor Case Could Open The Door For More Generics In The Fall
This article was originally published in The Pink Sheet Daily
FDA filed a notice of appeal challenging a court decision granting Ivax and Ranbaxy 180-day exclusivity for generic simvastatin.
You may also be interested in...
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.
It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.